Literature DB >> 12861735

Intravesical Bacillus Calmette-Guerin for treating bladder cancer.

Lee Ann Boyd1.   

Abstract

Bladder cancer continues to be a leading cause of malignant neoplasm in men. Since 1976, Bacillus Calmette-Guerin (BCG) has been a recommended treatment for superficial bladder malignancy. BCG treatment indications, administration, side effects, patient education, and nursing implications are discussed.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12861735

Source DB:  PubMed          Journal:  Urol Nurs        ISSN： 1053-816X


  3 in total

1.  A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients.

Authors:  Mark Kowalski; Joycelyn Entwistle; Jeannick Cizeau; Demi Niforos; Shauna Loewen; Wendy Chapman; Glen C MacDonald
Journal:  Drug Des Devel Ther       Date:  2010-11-15       Impact factor: 4.162

2.  Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review.

Authors:  Yuhui He; Ning Wang; Xiaofeng Zhou; Jianfeng Wang; Zhenshan Ding; Xing Chen; Yisen Deng
Journal:  BMJ Open       Date:  2018-04-17       Impact factor: 2.692

3.  First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity.

Authors:  Peter Ruf; Hartwig W Bauer; Alexandra Schoberth; Claudia Kellermann; Horst Lindhofer
Journal:  Cancer Immunol Immunother       Date:  2021-04-10       Impact factor: 6.968
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.